Clinical Trial Update: Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity [Phase 1]

View source ↗

Summary

Phase 1 single and multiple ascending dose study of AMG 513 in participants with obesity; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• AMG 513

Snippet

Sponsor: Amgen | Conditions: Cardiometabolic Disease | Phase 1 | Status: RECRUITING